Search

Author/Creator Pong, A

1. Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial. (14th October 2021)

Authors:
Segar, M W; Pandey, A; Cherney, D Z I; Cannon, C P; Cosentino, F; Dagogo-Jack, S; Pratley, R E; Shih, W J; Frederich, R; Cater, N B; Maldonado, M; Liu, J; Liu, C; Pong, A; McGuire, D K
Journal:
European heart journal
Issue:
Volume 42(2021)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV. (14th October 2021)

Authors:
Cherney, D Z I; Segar, M; Pandey, A; Cannon, C P; Cosentino, F; Dagogo-Jack, S; Pratley, R E; Frederich, R; Cater, N B; Maldonado, M; Liu, J; Liu, C.-C; Pong, A; McGuire, D K
Journal:
European heart journal
Issue:
Volume 42(2021)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search